Bio-Rad Laboratories Comprehensive Income 2010-2024 | BIO
Bio-Rad Laboratories comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Bio-Rad Laboratories comprehensive income for the quarter ending June 30, 2024 was $-0.451B, a 21.05% increase year-over-year.
- Bio-Rad Laboratories comprehensive income for 2023 was $-0.336B, a 28.02% decline from 2022.
- Bio-Rad Laboratories comprehensive income for 2022 was $-0.467B, a 165.92% increase from 2021.
- Bio-Rad Laboratories comprehensive income for 2021 was $-0.176B, a 162.15% decline from 2020.
| Bio-Rad Laboratories Annual Comprehensive Income (Millions of US $) |
|
|---|---|
| 2023 | $-336 |
| 2022 | $-467 |
| 2021 | $-176 |
| 2020 | $282 |
| 2019 | $-87 |
| 2018 | $-47 |
| 2017 | $739 |
| 2016 | $418 |
| 2015 | $382 |
| 2014 | $219 |
| 2013 | $341 |
| 2012 | $275 |
| 2011 | $199 |
| 2010 | $198 |
| 2009 | $133 |
| Bio-Rad Laboratories Quarterly Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024-06-30 | $-451 |
| 2024-03-31 | $-426 |
| 2023-12-31 | $-336 |
| 2023-09-30 | $-498 |
| 2023-06-30 | $-373 |
| 2023-03-31 | $-408 |
| 2022-12-31 | $-467 |
| 2022-09-30 | $-845 |
| 2022-06-30 | $-533 |
| 2022-03-31 | $-308 |
| 2021-12-31 | $-176 |
| 2021-09-30 | $-63 |
| 2021-06-30 | $125 |
| 2021-03-31 | $68 |
| 2020-12-31 | $282 |
| 2020-09-30 | $84 |
| 2020-06-30 | $-61 |
| 2020-03-31 | $-149 |
| 2019-12-31 | $-87 |
| 2019-09-30 | $-152 |
| 2019-06-30 | $-50 |
| 2019-03-31 | $-81 |
| 2018-12-31 | $-47 |
| 2018-09-30 | $-32 |
| 2018-06-30 | $-19 |
| 2018-03-31 | $104 |
| 2017-12-31 | $739 |
| 2017-09-30 | $617 |
| 2017-06-30 | $611 |
| 2017-03-31 | $517 |
| 2016-12-31 | $418 |
| 2016-09-30 | $521 |
| 2016-06-30 | $460 |
| 2016-03-31 | $415 |
| 2015-12-31 | $382 |
| 2015-09-30 | $379 |
| 2015-06-30 | $332 |
| 2015-03-31 | $207 |
| 2014-12-31 | $219 |
| 2014-09-30 | $261 |
| 2014-06-30 | $351 |
| 2014-03-31 | $373 |
| 2013-12-31 | $341 |
| 2013-09-30 | $316 |
| 2013-06-30 | $267 |
| 2013-03-31 | $269 |
| 2012-12-31 | $275 |
| 2012-09-30 | $249 |
| 2012-06-30 | $214 |
| 2012-03-31 | $256 |
| 2011-12-31 | $199 |
| 2011-09-30 | $213 |
| 2011-06-30 | $297 |
| 2011-03-31 | $230 |
| 2010-12-31 | $198 |
| 2010-09-30 | $160 |
| 2010-06-30 | $75 |
| 2010-03-31 | $116 |
| 2009-12-31 | $133 |
| 2009-09-30 | $125 |
| 2009-06-30 | $71 |
| 2009-03-31 | $16 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $9.489B | $2.671B |
| Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels outside the United States through subsidiaries which focus on sales, customer service and product distribution. The company operates through two reportable segments - Life Science segment which designs, manufactures, markets and services reagents, apparatus and instruments utilized for biological research. Clinical Diagnostics - This business markets and distributes products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians office laboratories, transfusion laboratories as well as insurance and forensic testing laboratories. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $199.879B | 25.82 |
| Stryker (SYK) | United States | $137.705B | 32.18 |
| Boston Scientific (BSX) | United States | $121.595B | 37.03 |
| Medtronic (MDT) | Ireland | $113.026B | 16.82 |
| EssilorLuxottica (ESLOY) | France | $104.378B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.118B | 35.17 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.437B | 0.00 |
| ResMed (RMD) | United States | $34.974B | 30.79 |
| Koninklijke Philips (PHG) | Netherlands | $29.016B | 22.05 |
| Terumo (TRUMY) | Japan | $27.876B | 39.37 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.644B | 13.63 |
| Baxter (BAX) | United States | $20.086B | 13.62 |
| Insulet (PODD) | United States | $16.555B | 69.65 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.426B | 0.00 |
| Demant (WILYY) | Denmark | $9.197B | 0.00 |
| BellRing Brands (BRBR) | United States | $7.672B | 32.44 |
| Lantheus Holdings (LNTH) | United States | $7.508B | 18.02 |
| ICU Medical (ICUI) | United States | $4.304B | 41.08 |
| TG Therapeutics (TGTX) | United States | $3.909B | 41.39 |
| Haemonetics (HAE) | United States | $3.870B | 19.14 |
| Perrigo (PRGO) | Ireland | $3.841B | 12.14 |
| GN Store Nord (GNNDY) | Denmark | $3.758B | 22.64 |
| Neogen (NEOG) | United States | $3.736B | 39.18 |
| Prestige Consumer Healthcare (PBH) | United States | $3.644B | 18.16 |
| Envista Holdings (NVST) | United States | $3.298B | 17.60 |
| QuidelOrtho (QDEL) | United States | $3.108B | 19.59 |
| Agios Pharmaceuticals (AGIO) | United States | $2.591B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.311B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $2.171B | 36.43 |
| LeMaitre Vascular (LMAT) | United States | $1.996B | 53.20 |
| AdaptHealth (AHCO) | United States | $1.524B | 11.00 |
| InMode (INMD) | Israel | $1.466B | 9.34 |
| Warby Parker (WRBY) | United States | $1.466B | 0.00 |
| AtriCure (ATRC) | United States | $1.363B | 0.00 |
| Owens & Minor (OMI) | United States | $1.219B | 9.41 |
| Verano Holdings (VRNOF) | United States | $1.114B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.094B | 0.00 |
| Evolus (EOLS) | United States | $1.023B | 0.00 |
| PetIQ (PETQ) | United States | $0.920B | 23.32 |
| Phibro Animal Health (PAHC) | United States | $0.897B | 18.61 |
| National Vision Holdings (EYE) | United States | $0.864B | 27.48 |
| Cresco Labs (CRLBF) | United States | $0.801B | 0.00 |
| Surmodics (SRDX) | United States | $0.561B | 119.09 |
| Quanterix (QTRX) | United States | $0.543B | 0.00 |
| ZimVie (ZIMV) | United States | $0.454B | 42.23 |
| VAREX IMAGING (VREX) | United States | $0.451B | 13.62 |
| Valneva SE (VALN) | France | $0.422B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.406B | 0.00 |
| Jin Medical (ZJYL) | China | $0.397B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.333B | 0.00 |
| Cerus (CERS) | United States | $0.330B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.321B | 8.29 |
| Aurora Cannabis (ACB) | Canada | $0.320B | 0.00 |
| Biote (BTMD) | United States | $0.319B | 14.70 |
| Viemed Healthcare (VMD) | United States | $0.287B | 30.79 |
| Sanara MedTech (SMTI) | United States | $0.272B | 0.00 |
| Zynex (ZYXI) | United States | $0.260B | 45.44 |
| Utah Medical Products (UTMD) | United States | $0.234B | 15.52 |
| Ayr Wellness (AYRWF) | United States | $0.232B | 0.00 |
| Omeros (OMER) | United States | $0.228B | 0.00 |
| MacroGenics (MGNX) | United States | $0.207B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.196B | 0.00 |
| High Tide (HITI) | Canada | $0.170B | 70.33 |
| Capricor Therapeutics (CAPR) | United States | $0.167B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.153B | 20.62 |
| Brainsway (BWAY) | Israel | $0.140B | 168.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.135B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.125B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.124B | 0.00 |
| Veru (VERU) | United States | $0.113B | 0.00 |
| Fonar (FONR) | United States | $0.110B | 11.15 |
| Jushi Holdings (JUSHF) | United States | $0.103B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.099B | 24.20 |
| InterCure (INCR) | Israel | $0.085B | 14.31 |
| Safety Shot (SHOT) | United States | $0.082B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.077B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.076B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.075B | 0.00 |
| Modular Medical (MODD) | United States | $0.073B | 0.00 |
| MariMed (MRMD) | United States | $0.065B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.056B | 3.63 |
| Exagen (XGN) | United States | $0.049B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.041B | 0.00 |
| Apyx Medical (APYX) | United States | $0.036B | 0.00 |
| Bright Green (BGXX) | United States | $0.028B | 0.00 |
| ImmuCell (ICCC) | United States | $0.028B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.026B | 0.00 |
| Nephros (NEPH) | United States | $0.019B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.011B | 0.00 |
| Agape ATP (ATPC) | $0.008B | 0.00 | |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Sharps Technology (STSS) | United States | $0.007B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.000B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 20.47 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |